A key developmental milestone has been reached following gene therapy, with some individuals with AADC deficiency reportedly thriving and showing significant progress, such as walking and talking. The treatment, Kebilidi, has been approved by the FDA, and research is ongoing to advance personalized treatments for rare diseases. The outcomes of gene therapy for AADC deficiency are being studied and tracked, with various approaches being explored, including different routes of administration.